Please try another search
On June 10, 2015, Dendreon Corp. went out of business as per its Chapter 7 liquidation filing under bankruptcy. Dendreon Corporation, a biotechnology company, focuses on the discovery, development, and commercialization of novel therapeutics to enhance cancer treatment options for patients. The company’s product portfolio includes active cellular immunotherapies and a small molecule product candidate that could be applicable to treating various types of cancers. Its product candidates under research and development includes DN24-02, an investigational active cellular immunotherapy, which is in Phase II clinical trial for the treatment of patients with bladder, breast, ovarian, and other solid tumors expressing HER2/neu; carbonic anhydrase 9, an antigen expressed in renal cell carcinoma; carcinoembryonic antigen, an antigen expressed in colorectal and other cancers; and Transient Receptor Potential, sub-family M 8, a small molecule that has completed Phase I clinical trial to treat various types of cancers. Dendreon Corporation was founded in 1992 and is headquartered in Seattle, Washington.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review